NovoCure Limited

NASDAQ:NVCR

Medical - Instruments & Supplies

Healthcare
$10.73 -19.66%

-$3.51 today

Market cap
$1.25B
Beta
0.92
P/E (TTM)
-9.5
EPS (TTM)
-$1.52
52W Low $9.82High $18.92

Volume 1.41M

Average 1.52M

NVCR Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

NovoCure LimitedNASDAQ: NVCR

Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026

Deferred tax liabilities remains negative

Q1 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier.

Context

  • Deferred tax liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred tax liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Tax Liabilities vs competitors

How NVCR compares with its peers on the latest reported figures

  • NVCR's Mar 2026 deferred tax liabilities of $0 is the highest of the 4 companies compared; the peer median is $0.
  • Deferred tax liabilities amounts to 0.0% of total assets for NVCR, versus a peer median of 0.0%.
NVCR Competitors Peer median
Deferred Tax Liabilities for NVCR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVCRNovoCure LimitedMar 2026$0 ——0.0%
PLSEPulse Biosciences, Inc.Jun 2026$0 ——0.0%
DCTHDelcath Systems, Inc.Mar 2026$0 ——0.0%
NPCENeuroPace, Inc.Mar 2026$0 ——0.0%
Peer median (excluding NVCR) $0——0.0%

Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents209.61M115.33M240.82M163.77M103.39M
Short-term Investments728.9M854.1M669.8M796.11M354.13M
Net Receivables97.41M106.03M77.11M102.07M115.35M
Inventory24.43M29.38M38.15M35.09M41.11M
Other Current Assets8.47M508K1.74M2.33M23.1M
Total Current Assets1.07B1.11B1.03B1.11B646.73M
Property, Plant & Equipment (Net)53.88M68.96M97.7M119.59M147M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets12.09M11.16M14.02M14.62M10.6M
Total Non-current Assets65.97M80.12M111.72M134.21M157.6M
Total Assets1.14B1.19B1.15B1.24B804.33M
Account Payables72.6M85.2M94.39M105.09M122.23M
Short-term Debt6.68M00558.16M11.66M
Tax Payables5.8M8.66M9.13M00
Deferred Revenue17.76M18.03M16.22M14.23M15.95M
Other Current Liabilities169K0009.03M
Total Current Liabilities142.6M158.78M179.12M756.38M223.23M
Long-term Debt562.22M565.51M568.82M97.3M236.69M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)6.48M2.88M000
Other Non-current Liabilities4.71M4.55M8.28M6.96M(37.71M)
Total Non-current Liabilities586.4M591.7M604.52M124.23M240.63M
Total Liabilities729M750.48M783.63M880.61M463.86M
Common Stock00000
Retained Earnings(685.93M)(778.46M)(985.5M)(1.15B)(1.29B)
Accumulated OCI(3.17M)(2.43M)(5.47M)(5.5M)(3.44M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity410.49M441.17M362.5M360.18M340.47M
Total Debt581.9M584.27M596.24M683.35M290M
Net Debt372.29M468.95M355.42M519.59M186.61M

NovoCure Limited

NASDAQ:NVCR

Intrinsic Alpha fair value

Locked

Current Price

$10.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.